Are there any situations where you would specifically not use IMRT/VMAT to treat post-operative gynecologic malignancies?  

For instance, RTOG 0418 did not allow clear cell or papillary serous histologies, but subsequent trials that allow IMRT have (GOG 0249, 0258, RTOG 1203, etc).  Are there other factors that effect your decision of 3D-CRT over IMRT?

Answer from: Radiation Oncologist at Academic Institution